This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lounis, N.
Right arrow Articles by Grosset, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lounis, N.
Right arrow Articles by Grosset, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2001, p. 3229-3230, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3229-3230.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Efficacies of Clarithromycin Regimens against Mycobacterium xenopi in Mice

Nacer Lounis,* Chantal Truffot-Pernot, Abdelhalim Bentoucha, Jerome Robert, Baohong Ji, and Jacques Grosset

Bactériologie-Hygiène, Faculté de Médecine Pitié-Salpêtrière, Paris, France

Received 11 April 2001/Returned for modification 4 June 2001/Accepted 6 August 2001

Mice were infected intravenously with 3.5 × 107 CFU of Mycobacterium xenopi and treated with various clarithromycin-containing regimens or left untreated for 4 weeks. All nine of the clarithromycin-containing regimens reduced the CFU counts to the levels below the pretreatment values, indicating that these regimens had a bactericidal effect on M. xenopi in mice. The rifampin-isoniazid-ethambutol regimen was significantly less bactericidal than clarithromycin alone or clarithromycin-containing combined regimens.

* Corresponding author. Mailing address: Laboratoire de Bactériologie-Hygiène, Faculté de Médecine Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, 75634 Paris, Cedex 13, France. Phone: (331) 40 77 97 46. Fax: (331) 45 82 75 77. E-mail: lounis{at}chups.jussieu.fr.

Antimicrobial Agents and Chemotherapy, November 2001, p. 3229-3230, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3229-3230.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Andrejak, C, Lescure, F-X, Pukenyte, E, Douadi, Y, Yazdanpanah, Y, Laurans, G, Schmit, J-L, Jounieaux, V, and the Xenopi Group, (2009). Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax 64: 291-296 [Abstract] [Full Text]  
  • Pandey, R., Khuller, G. K. (2006). Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother 57: 1146-1152 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»